Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simplification to darunavir/ritonavir monotherapy vs darunavir/ritonavir-based triple therapy in virologically suppressed HIV-1 infection
2006-006437-40Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darunavir in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Confirmed virologic response at weeks 48, 96 and 144 (ITT). Started Dec 2006; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-006437-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006437-40.